Industry

Ivonescimab in Combination with Chemotherapy Showed Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Global Phase III HARMONi Trial Evaluating Patients with EGFRm NSCLC after EGFR TKI Therapy; Positive Trend Observed in Overall Survival Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in … [Read more…]

On Track to Report Topline Data for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in September On Track to Select a STAT6 Development Candidate in 2H 2025 Conducting IND Enabling Studies of EPS-1421, an Oral KIT Inhibitor Candidate, in Development for the Treatment of Chronic Spontaneous … [Read more…]

BOSTON–(BUSINESS WIRE)–#histologymatters—Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, announced that United Healthcare has updated its cardiac imaging guidelines to fully align with recent recommendations from radiology benefit manager EviCore. United Healthcare’s new guidelines now include coronary computed tomography angiography (CTA) … [Read more…]

Upcoming ISG Provider Lens® report will examine providers that aid healthcare digital transformation through emerging technologies such as AI and data analytics STAMFORD, Conn.–(BUSINESS WIRE)–$III #AI–Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has launched a research study examining healthcare digital service providers’ capabilities to upgrade client technologies and … [Read more…]

One billion cells to power the next generation of AI models in biology SAN FRANCISCO–(BUSINESS WIRE)–Tahoe Therapeutics today announced $30 million in new funding to build the definitive foundational dataset for training Virtual Cell Models. With this, the team will generate one billion single-cell datapoints, mapping one million drug-patient interactions, a scale previously impossible. The … [Read more…]

Collaboration brings new ArcLight Academy training programs to The University of Texas at San Antonio (UTSA) Professional and Continuing Education (PaCE) students and staff starting this fall. Enhance your education with new programs offering grants and paid tuition, which are available to most applicants. SAN ANTONIO–(BUSINESS WIRE)–#EMT–The University of Texas at San Antonio (UTSA) Professional … [Read more…]

FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to purchase 11,000,000 shares of common stock to Harout Semerjian, Geron’s new President and Chief Executive Officer, as an inducement material to his acceptance of employment with Geron. … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Conflict Management for Pharmaceutical Executives Training Course” training has been added to ResearchAndMarkets.com’s offering. Effective conflict management is essential for pharmaceutical executives to navigate the complexities of a dynamic, globalised industry. This four-module webinar equips participants with vital strategies and tools to identify, address, and resolve workplace conflicts. Key topics include understanding the … [Read more…]

MURFREESBORO, Tenn.–(BUSINESS WIRE)–National HealthCare Corporation (NYSE American: NHC), the nation’s oldest publicly traded senior health care company, announced today net operating revenues for the quarter ended June 30, 2025 totaled $374,910,000 compared to $300,658,000 for the quarter ended June 30, 2024, an increase of 24.7%. The increase in net operating revenues for the second quarter … [Read more…]

MOBILE, Ala.–(BUSINESS WIRE)–TruBridge, Inc. (NASDAQ: TBRG), a healthcare solutions company, today announced financial results for the second quarter and six months ended June 30, 2025. Second Quarter 2025 Highlights* All comparisons are to the quarter ended June 30, 2024, unless otherwise noted Total bookings of $25.6 million compared to $23.3 million Total revenue of $85.7 … [Read more…]